Anthera Pharmaceuticals (ANTH) halts its VISTA-16 clinical study due to a lack of efficacy that...

|About: Anthera Pharmaceuticals, Inc. (ANTH)|By:, SA News Editor

Anthera Pharmaceuticals (ANTH) halts its VISTA-16 clinical study due to a lack of efficacy that could not be reasonably overcome in the remainder of the trial, following a recommendation by the Independent Data Safety Monitoring Board. ANTH -63.4% AH.